Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates
Mirum Pharmaceuticals (MIRM) reported strong Q3 results, exceeding both earnings and revenue estimates. The company posted a loss of $0.07 per share, significantly better than the Zacks Consensus Estimate of a $1.09 loss and a substantial improvement from the prior year's quarter. Revenue reached $79.8 million, surpassing expectations and demonstrating considerable year-over-year growth.
Mirum Pharmaceuticals (MIRM) Is Up 6.5% After First GAAP Profit And Higher Guidance - Has The Bull Case Changed?
Mirum Pharmaceuticals experienced a 6.5% stock increase following its first GAAP profit and raised full-year revenue guidance to about US$500 million. The company has also achieved new approvals and trial milestones for its rare disease portfolio, including LIVMARLI and CTEXLI. These developments are significantly impacting perceptions of Mirum’s long-term growth and its investment narrative.
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Record Revenues First GAAP Profitability And Key Trial Milestones
Mirum Pharmaceuticals (MIRM) has seen significant momentum due to record revenues, first GAAP profitability, and key trial completions. While a Simply Wall St narrative suggests the stock is 11.7% undervalued with a fair value of $106.60, this depends heavily on late-stage clinical data and execution, particularly for volixibat. However, the SWS model flags the stock as trading significantly below its fair value but notes its P/S ratio is above sector averages, indicating mixed signals for investors considering current valuation.
MIRM Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of Mirum Pharmaceuticals Inc (MIRM), detailing its revenue breakdown, profitability margins, and a comparison with competitors. Livmarli is identified as MIRM's largest revenue contributor at 69.3% ($92.23M), with Bile Acid Medicines also contributing. The company exhibits a strong gross margin of 81.02% but has negative operating and net margins, and a negative Return on Equity, positioning it as a significant player in the Pharmaceuticals industry with a $5.68B market cap.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Moderate Buy" from Analysts
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has received an average "Moderate Buy" rating from analysts, with a collective 12-month price target of $117.67. Despite missing Q4 EPS estimates, the company's revenue increased by 49.8% to $148.93 million, exceeding expectations. Corporate insiders have been net sellers, with the CEO and another insider selling a significant number of shares recently, though insiders still collectively own 14.36% of the company.
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?
Mirum Pharmaceuticals (MIRM) saw its shares increase by 5.1% due to higher than average trading volume, likely driven by positive developments in its phase III EXPAND study for Livmarli. Although revenue is expected to grow significantly, the consensus EPS estimate for the quarter has remained unchanged, and the stock currently holds a Zacks Rank #3 (Hold). Investors are advised to watch for trends in earnings estimate revisions to determine if the stock's recent strength will continue.
Mirum Pharmaceuticals (MIRM) Rises 5.1%: Can This Upward Momentum Continue?
Mirum Pharmaceuticals (MIRM) experienced a 5.1% stock surge, closing at $92.38, driven by positive developments in its phase III EXPAND clinical trial for Livmarli. Despite the recent stock increase, the company is projected to report a quarterly loss but expects a revenue increase of 33.6% year-over-year. Investors are advised to monitor the steadiness of earnings estimates, as a lack of positive revisions could hinder continued upward momentum.
Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi Year Surge?
Mirum Pharmaceuticals (MIRM) has seen significant multi-year gains but has been more volatile recently. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 75.8% at around $87.90 per share, while a Price/Sales (P/S) ratio analysis indicates it's slightly overvalued compared to its calculated "Fair Ratio." The article encourages investors to use "Narratives" for a more personalized valuation, reflecting varied community perspectives on the stock's fair value.
JPMorgan Chase & Co. Sells 380,067 Shares of Mirum Pharmaceuticals, Inc. $MIRM
JPMorgan Chase & Co. significantly reduced its stake in Mirum Pharmaceuticals, Inc. by selling 380,067 shares, decreasing its holdings by 79.1%. Despite this, other institutional investors like Eventide Asset Management, Wellington Management Group, and Arrowstreet Capital Limited Partnership substantially increased their positions. Mirum Pharmaceuticals recently missed EPS estimates but exceeded revenue expectations and holds a "Moderate Buy" consensus rating with an average target price of $117.67.
(MIRM) and the Role of Price-Sensitive Allocations
This article provides an in-depth analysis of Mirum Pharmaceuticals Inc. (NASDAQ: MIRM), indicating neutral near and mid-term readings with a long-term positive bias. It highlights an exceptional 43.2:1 risk-reward setup targeting a 12.5% gain versus 0.3% risk. The analysis also details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide potential investments.
Hennion & Walsh Asset Management Inc. Sells 17,560 Shares of Mirum Pharmaceuticals, Inc. $MIRM
Hennion & Walsh Asset Management Inc. significantly reduced its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 15.2% in Q4, selling 17,560 shares, though still holding 98,294 shares valued at $7.76 million. This comes amidst other institutional investors adjusting their positions, and notable insider sales by the COO and CEO in March, totaling over $11 million. Despite these sales and an EPS miss, analysts maintain a "Moderate Buy" rating with an average price target of $117.67, with the company reporting strong revenue growth of 49.8% year-over-year.
Tudor Investment Corp ET AL Makes New $2.03 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM
Tudor Investment Corp ET AL has made a new $2.03 million investment in Mirum Pharmaceuticals (NASDAQ:MIRM), acquiring 27,654 shares. This move is part of a broader trend of institutional interest, with Voloridge Investment Management significantly increasing its stake, and analysts maintaining a "Moderate Buy" rating for Mirum with a consensus price target of $117.67. Despite missing quarterly EPS estimates, Mirum exceeded revenue expectations, though insiders did sell a notable volume of shares recently
Mirum Pharmaceuticals Stock: Pipeline Progress and Rare Disease Focus for Long-Term Investor Value
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare pediatric liver diseases. Their lead product, LIVMARLI, is approved for Alagille syndrome and is being expanded for progressive familial intrahepatic cholestasis (PFIC). The company's pipeline also includes Volixibat and other candidates, showcasing a strategy for long-term growth and investor value in the rare disease space.
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $125.00
TD Cowen has raised its price target for Mirum Pharmaceuticals (NASDAQ:MIRM) to $125.00 from $117.00, maintaining a "buy" rating despite the company missing EPS estimates but beating revenue expectations in its latest quarterly report. Other analysts have also adjusted their price targets, and institutional investors have made recent changes to their holdings. Insider trading activity was mixed, with the COO selling shares and a director buying a significant amount.
Vanguard disaggregates holdings; Mirum (MIRM) shows 0 shares owned
Vanguard Group has filed an Amendment No. 1 Schedule 13G/A for Mirum Pharmaceuticals Inc (MIRM), reporting 0 beneficially owned shares and 0% class ownership. This change is due to an internal realignment on January 12, 2026, where certain subsidiaries will now report their holdings separately, in reliance on SEC Release No. 34-39538. Vanguard clarifies that these subsidiaries will continue to pursue the same investment strategies, and Vanguard itself no longer holds or is deemed to hold beneficial ownership of these disaggregated holdings.
Mirum Pharmaceuticals Insiders Sell US$1.6m Of Stock, Possibly Signalling Caution
A recent insider selling event at Mirum Pharmaceuticals (NASDAQ:MIRM) saw multiple insiders, including the Lead Independent Director and the President, sell shares totaling US$1.6 million over the past year. This significant selling activity suggests that some insiders may believe the stock is overvalued, as the average selling price of US$30.00 is higher than the current share price of US$27.08. While insider selling doesn't always signal future decline, it's often viewed as a more credible indicator of potential overvaluation compared to insider buying.
TD Cowen Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125
TD Cowen has reaffirmed its Buy rating for Mirum Pharmaceuticals (MIRM.US) and increased its price target to $125. This revision suggests a strong outlook for the company's financial performance and stock valuation, building on previous analyst confidence. The updated target price reflects an optimistic assessment of Mirum Pharmaceuticals' future growth and market position.
TD Cowen raises Mirum Pharmaceuticals stock price target to $125
TD Cowen has increased its price target for Mirum Pharmaceuticals (NASDAQ: MIRM) stock to $125 from $117, maintaining a Buy rating. This adjustment comes after the firm's review of clinical trial data for volixibat, which is expected to significantly reduce pruritus in patients, leading to an updated peak sales estimate of $350 million for the drug. Other analysts from Citizens and Morgan Stanley have also reiterated bullish ratings and price targets, highlighting Mirum's progress in its treatment pipeline.
Why Mirum Pharmaceuticals (MIRM) Is Down 9.0% After Completing Phase 3 EXPAND Trial Enrollment
Mirum Pharmaceuticals' stock fell 9.0% despite completing enrollment for its Phase 3 EXPAND trial of LIVMARLI, a drug for rare cholestatic liver diseases. The company aims to broaden LIVMARLI's reach and diversify its pipeline with other trials like AZURE-1 and AZURE-4 for brelovitug, countering its current reliance on LIVMARLI. Topline data for EXPAND is expected in Q4 2026, while analysts are cautiously evaluating the company's future revenue and earnings potential amidst evolving regulatory and reimbursement challenges.
Mirum Pharmaceuticals (NASDAQ:MIRM) Receives Buy Rating from HC Wainwright
HC Wainwright reiterated a "Buy" rating for Mirum Pharmaceuticals (NASDAQ:MIRM) with a $130 price target, suggesting a potential upside of nearly 47%. This comes despite the company reporting an earnings per share (EPS) miss last quarter, though revenue increased significantly. Analyst consensus rates MIRM as a "Moderate Buy" with an average price target of $117.
Mirum Pharmaceuticals (MIRM) completes enrollment for phase 3 EXPAND study of LIVMARLI
NULL
Mirum Pharmaceuticals (MIRM) Completes Enrollment for Phase 3 EXPAND Study of LIVMARLI
Mirum Pharmaceuticals (MIRM) has announced the completion of enrollment for its Phase 3 EXPAND study, evaluating LIVMARLI (maralixibat) for cholestatic pruritus in patients with rare cholestatic liver diseases. This study aims to broaden the drug's label beyond Alagille syndrome and progressive familial intrahepatic cholestasis, addressing debilitating itching and limited treatment options for a wider patient population. Topline data from the study is anticipated in Q4 2026.
MIRM SEC Filings - Mirum Pharmaceuticals 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Mirum Pharmaceuticals (MIRM) SEC filings, including annual, quarterly, and material event reports. It details recent insider transactions and equity awards for executives like CEO Christopher Peetz and CFO Eric Bjerkholt, as well as sales by insiders to cover tax obligations. The platform also offers AI-powered summaries to help investors understand key aspects of these regulatory documents.
MIRM SEC Filings - Mirum Pharmaceuticals 10-K, 10-Q, 8-K Forms
This page provides access to Mirum Pharmaceuticals (MIRM) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms. It highlights recent filings covering merger agreements, private placements, and corporate financial updates, enhanced with AI-powered summaries for quick understanding. The article also includes details of recent Form 4 insider transactions by SVP Jolanda Howe.
Mirum Pharmaceuticals (MIRM) files Form 144: proposed resale of vested RSUs
Mirum Pharmaceuticals (MIRM) has filed a Form 144, indicating proposed sales of Common Stock deriving from vested Restricted Stock Units under a registered plan. The filing specifies Morgan Stanley Smith Barney LLC as the broker and details recent dispositions by a holder, Jolanda Howe, in January and February 2026. This SEC filing offers insight into insider selling activities, with the stock acquired through compensation for services rendered to the issuer.
Mirum (MIRM) CEO sells shares to cover tax from RSU vesting
Mirum Pharmaceuticals CEO Christopher Peetz exercised performance restricted stock units for 75,000 shares and subsequently sold 40,985 shares at an average price of $91.9779. This sale was explicitly stated to cover tax withholding obligations related to the RSU vesting, rather than being a discretionary sale. Following these transactions, Mr. Peetz directly holds 194,309 shares, with an additional 187,500 shares held indirectly by The Peetz Family Trust.
Mirum (MIRM) CMO exercises performance RSUs, sells 7,287 shares for tax
Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, exercised performance-based Restricted Stock Units (RSUs) and subsequently sold 7,287 shares of common stock at an average price of $91.9779 per share to cover tax withholding obligations. After these transactions, Quan directly holds 18,864 Mirum common shares. The remaining performance units are scheduled to vest in two-thirds on March 15, 2026, and one-third on March 15, 2027.
Mirum (NASDAQ: MIRM) SVP exercises PRSUs, sells 4,732 shares for taxes
Jolanda Howe, Senior Vice President and Global Controller at Mirum Pharmaceuticals, exercised performance restricted stock units (PRSUs) for 8,658 shares of common stock. Subsequently, she sold 4,732 shares at $91.9779 each to cover tax withholding obligations associated with the PRSU vesting. After these transactions, Howe retained 8,429 Mirum Pharmaceuticals shares.
Penn Capital Management Company LLC Sells 34,265 Shares of Mirum Pharmaceuticals, Inc. $MIRM
Penn Capital Management Company LLC reduced its stake in Mirum Pharmaceuticals, Inc. by 10% in the third quarter, selling 34,265 shares, although Mirum remains its fourth-largest holding. Despite this reduction, the company maintains a significant investment value of $22.63 million in Mirum. The article also notes recent clustered insider selling by Mirum executives, alongside positive news regarding the completion of enrollment for a key Phase 3 study for LIVMARLI, with topline data expected in Q4 2026.
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells 16,515 Shares of Stock
Mirum Pharmaceuticals (NASDAQ:MIRM) COO Peter Radovich sold 16,515 shares of company stock on March 16th at an average price of $91.98, totaling approximately $1.52 million. This sale reduced his stake by 29.08% to 40,272 shares. The company's stock shows recent strength, trading at $96.55, and analysts hold a "Moderate Buy" rating with a consensus target price of $117.
Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Joanne Quan Sells 7,287 Shares
Mirum Pharmaceuticals (NASDAQ:MIRM) insider Joanne Quan sold 7,287 shares of the company's stock on March 16, 2026, for a total of $670,258.26, reducing her holdings by 27.87%. This sale follows previous transactions in January. Despite an EPS miss, Mirum's revenue beat expectations, leading to a 4.2% stock increase and a consensus "Moderate Buy" rating from analysts with an average price target of $117.
Mirum Pharmaceuticals (NASDAQ: MIRM) insider files to sell 16,515 shares
An insider at Mirum Pharmaceuticals (NASDAQ: MIRM) has filed a Form 144 to sell 16,515 shares of common stock, valued at approximately $1.53 million, acquired through Restricted Stock Units that vested on March 15, 2026. The filing also notes previous open-market sales by Peter Radovich totaling 8,156 shares across January and February 2026. This filing indicates a proposed sale of vested compensation and past dispositions.
Mirum (MIRM) president sells 16,515 shares, exercises 30,220 RSUs
Mirum Pharmaceuticals' President and COO, Peter Radovich, exercised 30,220 performance restricted stock units (RSUs) into common stock and subsequently sold 16,515 shares to cover tax withholding obligations. After these transactions, Radovich directly holds 40,272 common shares and retains 11,500 outstanding RSUs with future vesting dates. Analysts view this as a routine compensation event with minimal impact on the stock's informational value.
Mirum Pharmaceuticals (NASDAQ: MIRM) insider sells vested RSUs totaling multiple transactions
Mirum Pharmaceuticals (NASDAQ: MIRM) reported multiple transactions of common stock by insider Christopher Peetz, involving the sale of vested Restricted Stock Units (RSUs). These sales, conducted on three separate dates in early 2026, totaled 7,098, 6,831, and 9,108 shares, respectively, originating as compensation. The transactions were reported via Form 144, indicating routine insider dispositions rather than new stock issuances or dilution events for the company.
[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity
Mirum Pharmaceuticals director Saira Ramasastry exercised stock options for 2,000 shares at $23.51 per share and subsequently sold those 2,000 shares in an open-market transaction at $90.76 per share on March 16, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2025, indicating that the activity was scheduled in advance. Following the sale, she no longer directly holds these 2,000 common shares.
Aquatic Capital Management LLC Boosts Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM
Aquatic Capital Management LLC significantly increased its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 73.3% in the third quarter, now owning 63,946 shares valued at $4.688 million. This comes as other institutional investors also adjusted their positions, and the company reported quarterly earnings that missed consensus estimates but revenue that exceeded expectations. Analysts generally maintain a "Moderate Buy" rating for Mirum Pharmaceuticals, with a consensus target price of $117.00 despite recent insider stock sales.
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $670,258.26 in Stock
Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt sold 7,287 shares of the company's stock on March 16th for over $670,000, reducing his holding by 12.77%. Despite missing EPS estimates, the company's revenue grew by 49.8% year-over-year. Analysts have a "Moderate Buy" consensus rating with a $117 price target for the stock.
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals has announced the completion of enrollment for its Phase 3 EXPAND study of LIVMARLI® (maralixibat). This study evaluates the treatment for cholestatic pruritus in patients aged 6 months or older with rare cholestatic liver diseases, including biliary atresia, aiming to expand the drug's label beyond its current approvals for Alagille syndrome and PFIC. Topline data from the study are anticipated in the fourth quarter of 2026.
Saira Ramasastry to sell 2,000 shares via option exercise (NASDAQ: MIRM)
Saira Ramasastry, a holder of Mirum Pharmaceuticals (NASDAQ: MIRM) stock, has filed a Form 144 indicating a proposed sale of 2,000 shares through a stock option exercise on March 16, 2026. This filing is administrative in nature and includes details of previous dispositions by Ramasastry. Analysts consider this a routine transaction with neutral impact on the company.
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI
Mirum Pharmaceuticals has completed enrollment for its Phase 3 EXPAND study of LIVMARLI (maralixibat), targeting cholestatic pruritus in patients with rare cholestatic liver diseases, including biliary atresia. This study aims to expand LIVMARLI's label beyond its current approvals for Alagille syndrome and PFIC. Topline data from the randomized, double-blind, placebo-controlled study are anticipated in the fourth quarter of 2026.
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals has announced the completion of enrollment in its Phase 3 EXPAND study of LIVMARLI® (maralixibat). This study evaluates the treatment for cholestatic pruritus in patients aged 6 months or older with various rare cholestatic liver diseases, including biliary atresia. Topline data from the study are anticipated in the fourth quarter of 2026, potentially expanding LIVMARLI's label to address broader unmet medical needs.
Algert Global LLC Buys 31,250 Shares of Mirum Pharmaceuticals, Inc. $MIRM
Algert Global LLC increased its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 19.6% in the third quarter, purchasing an additional 31,250 shares. This brings their total holdings to 190,599 shares, valued at approximately $13.97 million. Other institutional investors have also adjusted their positions, and the company recently released its quarterly earnings, reporting a revenue of $148.93 million.
Eventide Asset Management LLC Sells 114,922 Shares of Mirum Pharmaceuticals, Inc. $MIRM
Eventide Asset Management LLC reduced its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 4.4%, selling 114,922 shares but still retaining over 2.5 million shares valued at $184.9 million, making it their second-largest holding. Meanwhile, Mirum Pharmaceuticals reported a quarterly EPS miss of ($0.11) against an expected $0.02, though revenue increased by 49.8% to $148.9 million. Analysts maintain a "Moderate Buy" consensus rating for the company, with a target price of $117.00.
Mirum Pharmaceuticals, Inc. $MIRM Stock Holdings Reduced by Boone Capital Management LLC
Boone Capital Management LLC has reduced its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 16.5% during the third quarter, now holding 535,732 shares valued at $39.28 million, making it their second-largest position. Despite this reduction, analyst sentiment remains largely positive with a "Moderate Buy" rating and an average price target of $117. The company reported a 49.8% year-over-year revenue increase to $148.93 million, beating estimates, but posted an EPS loss of $0.11 and remains unprofitable.
Does Advancing Brelovitug Into Late-Stage HDV Trials Change The Bull Case For Mirum Pharmaceuticals (MIRM)?
Mirum Pharmaceuticals recently announced that its brelovitug therapy for chronic hepatitis delta virus (HDV) has progressed into late-stage clinical trials, with Phase 3 AZURE-1 enrollment complete and AZURE-4 screening completed. This development expands Mirum's potential rare liver disease portfolio, although its near-term investment narrative remains largely tied to the success of existing bile-acid therapies like Livmarli and forthcoming pivotal trial readouts. While the HDV progress is incremental, it could influence long-term growth and investor sentiment regarding the company's diversification beyond its current revenue concentration.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. announced inducement grants to five new employees on March 11, 2026, as per Nasdaq Listing Rule 5635(c)(4). These awards include non-qualified stock options for 5,400 shares and 6,800 restricted stock units (RSUs). The grants aim to incentivize new hires, with stock options vesting over four years and RSUs over three years, subject to continued employment.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals announced the grant of inducement awards to five new employees, consisting of non-qualified stock options and restricted stock units (RSUs). These awards, approved by the Compensation Committee, are in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $91.75 and vest over four years, while RSUs vest over three years, both contingent on continued employment.
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Key Phase 3 Brelovitug Trial Milestones
Mirum Pharmaceuticals (MIRM) has completed key Phase 3 trial milestones for its drug brelovitug, generating renewed interest in the stock despite a recent 14.10% share price decline over 30 days. The company's valuation indicates a significant discount to analyst price targets and intrinsic value, leading to questions about a potential buying opportunity. The analysis highlights mixed signals regarding Mirum's value and risk, suggesting investors should explore further metrics and consider other investment ideas in the rare disease space.
Mirum expands into liver diseases with Bluejay Therapeutics acquisition
The provided content is empty. Therefore, a summary cannot be generated.
Teachers Retirement System of The State of Kentucky Invests $1.08 Million in Mirum Pharmaceuticals, Inc. $MIRM
The Teachers Retirement System of The State of Kentucky has invested $1.08 million in Mirum Pharmaceuticals (NASDAQ:MIRM) by acquiring 14,724 shares in the third quarter. This move comes as other institutional investors have also adjusted their stakes in the company. Mirum Pharmaceuticals recently reported missing EPS estimates but beat revenue expectations, with analysts maintaining a "Moderate Buy" rating for the stock.
